Overview

Location [1]
9p13.3
Pathway
DNA damage/repair
Protein [2]
Fanconi anemia group G protein
Synonyms [1]
FAG, XRCC9

Fanconi anemia, complementation group G (FANCG) is a gene that encodes a protein that is a member of the Fanconi anemia complementation group. The protein complex functions in the heterogeneous recessive disorder Fanconi anemia that causes cytogenetic instability, hypersensitivity to DNA crosslinking agents, increases chromosomal breakage, and defective DNA repair. Missense, nonsense, and silent mutations are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.

FANCG is altered in 1.33% of all cancers with lung adenocarcinoma, colon adenocarcinoma, melanoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].

FANCG GENIE Cases - Top Diseases

The most common alterations in FANCG are FANCG Mutation (1.10%), FANCG Amplification (0.19%), FANCG X494_splice (0.04%), FANCG A265V (0.04%), and FANCG A607T (0.06%) [3].

FANCG GENIE Cases - Top Alterations

Significance of FANCG in Diseases

Malignant Solid Tumor +

Breast Carcinoma +

Prostate Adenocarcinoma +

Ovarian Carcinoma +

Prostate Carcinoma +

Primary Peritoneal Carcinoma +

Fallopian Tube Carcinoma +

Small Cell Lung Carcinoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Gastric Carcinoma +

Pancreatic Adenocarcinoma +

Endometrial Carcinoma +

Non-Small Cell Lung Carcinoma +

Urothelial Carcinoma +

Pancreatic Carcinoma +

Colorectal Carcinoma +

Soft Tissue Sarcoma +

Cervical Carcinoma +

Esophageal Carcinoma +

High Grade Ovarian Serous Adenocarcinoma +

Head And Neck Carcinoma +

Squamous Cell Lung Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Non-Hodgkin Lymphoma +

Gastrointestinal Stromal Tumor +

Osteosarcoma +

Melanoma +

Medulloblastoma +

Neuroblastoma +

Malignant Small Intestinal Neoplasm +

Ewing Sarcoma +

Malignant Central Nervous System Neoplasm +

Glioma +

Malignant Intestinal Neoplasm +

Colorectal Adenocarcinoma +

Cancer +

Bladder Carcinoma +

Bladder Urothelial Carcinoma +

Multiple Myeloma +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Malignant Esophagogastric Neoplasm +

Malignant Ovarian Epithelial Tumor +

Bile Duct Adenocarcinoma +

Cholangiocarcinoma +

Gastric Adenocarcinoma +

Malignant Gastric Neoplasm +

Biliary Tract Carcinoma +

Esophageal Adenocarcinoma +

Clear Cell Renal Cell Carcinoma +

Malignant Mesothelioma +

Ampulla Of Vater Carcinoma +

Anal Carcinoma +

B-Cell Non-Hodgkin Lymphoma +

Diffuse Large B-Cell Lymphoma +

Leiomyosarcoma +

Low Grade Ovarian Serous Adenocarcinoma +

Mantle Cell Lymphoma +

Ovarian Clear Cell Adenocarcinoma +

Pancreatic Ductal Adenocarcinoma +

Penile Carcinoma +

Rhabdomyosarcoma +

Vaginal Carcinoma +

Vulvar Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.